
    
      A phase II, double-masked, randomized, placebo-controlled, parallel-group and multicenter
      clinical trial, to evaluate and compared the clinical efficacy and safety of four doses of
      PRO-118 ophthalmic solution ( PRO-118 0.015% qd, PRO-118 0.015% twice daily , PRO-118 0.020%
      qd, PRO-118 0.020% twice daily) for the treatment of seasonal (SAC) and perennial (PAC)
      allergic conjunctivitis.
    
  